• mAbxience will support development of the antibody moiety of ONC001, from Cell Line Development through manufacture of GMP material for a planned Phase I clinical trial.  
  • The agreement provides OncoPrecision with access to mAbxience’s development and manufacturing expertise, strengthening the program’s clinical and industrial readiness and supporting future growth and financing opportunities. 
  • mAbxience has made a strategic investment in OncoPrecision, and Jurgen Van Broeck, Chief Executive Officer of mAbxience, will join OncoPrecision’s Board of Directors as an Observer. 

Madrid, Spain. November 18th, 2026 — mAbxience, a wholly owned company of Fresenius SE & Co. KGaA, and OncoPrecision, a biotechnology company pioneering first-in-class precision therapies for hard-to-treat cancers through the integration of patient-derived biology and AI, headquartered in New York City; today announced an investment, development and manufacturing agreement for ONC001, OncoPrecision’s lead antibody-drug conjugate (ADC) candidate. 

Under the terms of the agreement, mAbxience will be responsible for the development program of the antibody moiety of ONC001, covering activities from Cell Line Development (CLD) through process and analytical development, as well as the manufacture of GMP-grade material to support the program’s planned Phase I clinical trial.  

ONC001 is a first-in-class CD64-targeting ADC designed to eliminate leukemic monocytes and tumor-associated macrophages, with lead indications in monocytic acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML) — aggressive blood cancers with few effective options and a median survival measured in months. ONC001 was first publicly disclosed in an oral presentation at the 2025 American Society of Hematology (ASH) Annual Meeting and is advancing towards first-in-human studies.   

As part of the agreement, mAbxience will contribute with its scientific expertise, industrial capabilities, and Smart CoGs approach with its extensive experience in antibody development by supporting the program through the manufacture of the first GMP batch for clinical use. mAbxience has made a strategic investment in OncoPrecision and Jurgen Van Broeck, Chief Executive Officer of mAbxience, will join OncoPrecision’s Board of Directors as an Observer. Financial terms of the investment remain confidential. José Ramón Millán, Global Portfolio, CDMO & Partnering Director at mAbxience, said: “We are excited to partner with OncoPrecision on the development of ONC001, a promising ADC candidate that exemplifies the innovation emerging in oncology today. By bringing together our capabilities and long-term commitment, we aim to accelerate ONC001’s path to the clinic while creating sustainable value for both companies.” 

Jurgen Van Broeck, Chief Executive Officer of mAbxience, said: “I’m pleased to support OncoPrecision through this partnership and as a Board Observer as they advance ONC001 towards Phase I studies and continue to make progress with their first-in-class pipeline.” 

Tarek Ali Zaki, Co-Founder and Chief Executive Officer of OncoPrecision, said: “We’re thrilled to partner with mAbxience to accelerate ONC001’s path to the clinic through their world-class manufacturing capabilities and regulatory expertise. Bringing a fully-integrated biopharmaceutical partner with a shared vision of delivering meaningful medicines to patients marks an important step towards our company’s next stage.” 

By combining OncoPrecision’s first-in-class candidate developed with its translational patient-derived discovery platform with mAbxience’s proven expertise in antibody development, process development, technology transfer, and GMP manufacturing, the two companies aim to accelerate the advancement of ONC001 toward first-in-human studies. 

About mAbxience 

mAbxience is a Spanish-based company specializing in the development, production and commercialization of biopharmaceuticals. mAbxience is a wholly owned company of Fresenius SE & Co. KGaA and part of Fresenius Kabi’s Biopharma business.  

With over fifteen years of expertise, mAbxience’s mission is clear: to provide accessible, affordable medicines across the globe, aiming to enhance quality of life by ensuring universal access to high-caliber medicines. 

With four approved products and a robust pipeline in development, mAbxience has established a B2B presence in over 100 markets. Alongside this, the company has formed a network with more than 40 partners and built a dedicated team of over 1,300 professionals. 

Its three multiproduct facilities, located in Europe and South America, have obtained GMP approval from esteemed regulatory bodies, including the FDA, EMA and others. 

Furthermore, as a global biopharmaceutical expert, mAbxience specializes in Contract Development and Manufacturing Organization (CDMO) services, utilizing advanced technology and innovative platforms to deliver integrated manufacturing solutions. For more insights into mAbxience, our biosimilars and CDMO business, please visit our website (www.mabxience.com) or connect with us on LinkedIn. 

 

mAbxience media contact: 

Miguel Martínez-Cava, Corporate Affairs & Marketing Associate Director: miguel.martinezcava@mabxience.com 

Sandra Aguilar, Communication Manager: sandra.aguilar@mabxience.com  

Share this post